content: SECURITIES AND EXCHANGE COMMISSION
                                        WASHINGTON, DC  20549
  
                                          ________________
  
                                              FORM 8-K
  
                                           CURRENT REPORT
                                 PURSUANT TO SECTION 13 OR 15(D) OF
                                 THE SECURITIES EXCHANGE ACT OF 1934
  
  
                   Date of report (Date of earliest event reported)  May 25, 1995
  
  
                                         SCIOS NOVA INC.                    
                         (Exact Name of Registrant as Specified in Charter)
  
  
  
             Delaware                       0-11749            95-3701481
   (State of Other Jurisdiction           (Commission         (IRS Employer
         of Incorporation)               File Number)      Identification No.)
  
  
  
                       2450 Bayshore Parkway, Mountain View, California  94043
                              (Address of Principal Executive Offices)
  
  
  
                 Registrant's telephone number, including area code 415-966-1550
  
  
  
  
  
  
  
  <PAGE>
  Item 5.  Other Events
  
          On May 25, 1995, Scios Nova Inc. was served with three complaints filed 
  in the United States District Court for the Northern District of California 
  by three shareholders.  The actions were filed against the Company and 
  Richard Casey, its Chairman and Chief Executive Officer.  The plaintiffs, who 
  seek to represent a class of persons who purchased common stock of the 
  Company between October 6, 1993 and May 2, 1995, assert claims against the 
  defendants for violations of Sections 10(b) and 20(a) of the Securities and 
  Exchange Act of 1934 in connection with Company statements regarding one of 
  its products, AURICULIN -Registered Trademark- anaritide.  
  
          The Company believes that it has meritorious defenses to the claims 
  and intends to mount a vigorous defense.  
  
  
  
  
  
  
  
          Pursuant to the requirements of the Securities Exchange Act of 1934, the
  registrant has duly caused this amendment to be signed on its behalf of the
  undersigned, thereunto duly authorized.  
  
                                         SCIOS NOVA INC.
  
  
  Date:  June 8, 1995                    By:  /s/ John H. Newman         
                                              John H. Newman
                                              Vice President of Legal Affairs
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "FORM 8-K", "secsgml_size_bytes": 2386}]
metadata_filer: {"company-data": {"conformed-name": "SCIOS NOVA INC", "cik": "0000726512", "assigned-sic": "2834", "irs-number": "953701481", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-11749", "film-number": "95545848"}, "business-address": {"street1": "2450 BAYSHORE PKWY", "city": "MOUNTAIN VIEW", "state": "CA", "zip": "94043", "phone": "4159661550"}, "mail-address": {"street1": "2450 BAYSHORE PARKWAY", "city": "MOUNTAIN VIEW", "state": "CA", "zip": "94043"}, "former-company": [{"former-conformed-name": "SCIOS INC", "date-changed": "19920703"}, {"former-conformed-name": "CALIFORNIA BIOTECHNOLOGY INC", "date-changed": "19920302"}]}
text: SECURITIES AND EXCHANGE COMMISSION
                                        WASHINGTON, DC  20549
  
                                          ________________
  
                                              FORM 8-K
  
                                           CURRENT REPORT
                                 PURSUANT TO SECTION 13 OR 15(D) OF
                                 THE SECURITIES EXCHANGE ACT OF 1934
  
                   Date of report (Date of earliest event reported)  May 25, 1995
  
                                         SCIOS NOVA INC.                    
                         (Exact Name of Registrant as Specified in Charter)
  
             Delaware                       0-11749            95-3701481
   (State of Other Jurisdiction           (Commission         (IRS Employer
         of Incorporation)               File Number)      Identification No.)
  
                       2450 Bayshore Parkway, Mountain View, California  94043
                              (Address of Principal Executive Offices)
  
                 Registrant's telephone number, including area code 415-966-1550
  Item 5.  Other Events
  
          On May 25, 1995, Scios Nova Inc. was served with three complaints filed 
  in the United States District Court for the Northern District of California 
  by three shareholders.  The actions were filed against the Company and 
  Richard Casey, its Chairman and Chief Executive Officer.  The plaintiffs, who 
  seek to represent a class of persons who purchased common stock of the 
  Company between October 6, 1993 and May 2, 1995, assert claims against the 
  defendants for violations of Sections 10(b) and 20(a) of the Securities and 
  Exchange Act of 1934 in connection with Company statements regarding one of 
  its products, AURICULIN -Registered Trademark- anaritide.  
  
          The Company believes that it has meritorious defenses to the claims 
  and intends to mount a vigorous defense.  
  
          Pursuant to the requirements of the Securities Exchange Act of 1934, the
  registrant has duly caused this amendment to be signed on its behalf of the
  undersigned, thereunto duly authorized.  
  
                                         SCIOS NOVA INC.
  
  Date:  June 8, 1995                    By:  /s/ John H. Newman         
                                              John H. Newman
                                              Vice President of Legal Affairs